Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 16420-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#16420-1-AP, RRID:AB_2294111
- Product name
- FUCA1 antibody
- Antibody type
- Polyclonal
- Description
- FUCA1 antibody (Cat. #16420-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer.
Alpha-L-fucosidase-1 is a diagnostic marker that distinguishes mucoepidermoid carcinoma from squamous cell carcinoma.
Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients.
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
High Resolution Proteomic Analysis of the Cervical Cancer Cell Lines Secretome Documents Deregulation of Multiple Proteases.
Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.
Xiao Y, Jiang X, Yin K, Miao T, Lu H, Wang W, Ma L, Zhao Y, Liu C, Qiao Y, Zhang P
Oncogenesis 2023 Mar 3;12(1):12
Oncogenesis 2023 Mar 3;12(1):12
Alpha-L-fucosidase-1 is a diagnostic marker that distinguishes mucoepidermoid carcinoma from squamous cell carcinoma.
Ishida S, Kayamori K, Sakamoto K, Yukimori A, Kugimoto T, Harada H, Ikeda T
Pathology international 2019 Feb;69(2):76-85
Pathology international 2019 Feb;69(2):76-85
Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients.
Bonin S, Parascandolo A, Aversa C, Barbazza R, Tsuchida N, Castellone MD, Stanta G, Vecchio G
Oncotarget 2018 Mar 16;9(20):15228-15238
Oncotarget 2018 Mar 16;9(20):15228-15238
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A
Oncotarget 2017 Sep 19;8(41):69435-69455
Oncotarget 2017 Sep 19;8(41):69435-69455
High Resolution Proteomic Analysis of the Cervical Cancer Cell Lines Secretome Documents Deregulation of Multiple Proteases.
Pappa KI, Kontostathi G, Makridakis M, Lygirou V, Zoidakis J, Daskalakis G, Anagnou NP
Cancer genomics & proteomics 2017 Nov-Dec;14(6):507-521
Cancer genomics & proteomics 2017 Nov-Dec;14(6):507-521
Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.
Vecchio G, Parascandolo A, Allocca C, Ugolini C, Basolo F, Moracci M, Strazzulli A, Cobucci-Ponzano B, Laukkanen MO, Castellone MD, Tsuchida N
Oncotarget 2017 Apr 18;8(16):27075-27092
Oncotarget 2017 Apr 18;8(16):27075-27092
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human liver using 16420-1-AP(FUCA1 antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The FUCA1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human FUCA1. This antibody recognizes human,mouse,rat antigen. The FUCA1 antibody has been validated for the following applications: ELISA, IHC analysis.
